Profile Details

Request Service

★★★★★

☆☆☆☆☆

USD 200 /hr

★★★★★

☆☆☆☆☆

Hire Dr. Leah Price

Israel

USD 200 /hr

Statistical Consultant with 15+ years of experience

Profile Summary

Provide comprehensive statistical consulting to a variety of clients for more than 15 years supporting projects from the design stage to completion. Biostatistician at a large oncology hospital for over five years. Co-author on more than 60 papers. On two large grants, oversaw data management, designed clinical trials (phase I, II, III), maintained SAP and analyzed results of clinical trials. For over 10 years responsible for statistical guidance and analysis of the largest world-wide proficiency panel for commonly used immune monitoring assays.

Subject Matter Expertise

• ☆ Data Analysis
• ☆ Biostatistics
• ☆ Medical Statistics
• ☆ Assays

Services

• Writing
• Scientific consulting
• Data Science
• Clinical Research Consulting
• Statistical review
• Experiment design

Data Science Data visualization, Analytical report, Analysis from dataset, Quantitative analysis

Statistical review Verify statistical analysis, Conduct simple analysis, Conduct complex analyses, Recommend suitable tests, Other

Clinical Research Consulting Design a clinical trial, Perform statistical analysis, Get help with research & development, Write a clinical case report, Prepare regulatory documents

Work Experience

• Director

  LBPrice Statistical Consulting

  March 2014 - Present

• Graduate Research Biostatistician

  New York University School of Medicine

  September 2006 - September 2013

• Statistical Consultant

  Home based Independent Consultant

  September 2005 - September 2013

• Research Biostatistician

  Memorial Sloan Kettering Cancer Center

  August 2001 - August 2006

Education

• PhD Biostatistics

  New York University

  September 2006 - September 2013

• MS Statistics

  Carleton University

  September 2000 - August 2001

Publications

JOURNAL ARTICLE
• (2019). Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis . Leukemia and Lymphoma.
• Gupta, V., Kosiorek, H.E., Mead, A., Klisovic, R.B., Galvin, J.P., Berenzon, D., Yacoub, A., Viswabandya, A., Mesa, R.A., Goldberg, J., et al.(2019). Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study . Biology of Blood and Marrow Transplantation. 25. (2). p. 256-264.
• Rampal, R.K., Mascarenhas, J.O., Rampal, R.K., Mascarenhas, J.O., Kosiorek, H.E., Price, L., Berenzon, D., Hexner, E., Abboud, C.N., Kremyanskaya, M., et al.(2018). Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms . Blood advances. 2. (24). p. 3572-3580.
• Janetzki, S., Janetzki, S., Price, L., Schroeder, H., Britten, C.M., Welters, M.J.P., Janetzki, S., Price, L., Schroeder, H., Britten, C.M., et al.(2015). Guidelines for the automated evaluation of Elispot assays . Nature Protocols. 10. (7). p. 1098-1115.
• Hexner, E.O., Mascarenhas, J., Prchal, J., Roboz, G.J., Baer, M.R., Ritchie, E.K., Leibowitz, D., Demakos, E.P., Miller, C., Siuty, J., et al.(2015). Phase I dose escalation study of lestaurtinib in patients with myelofibrosis . Leukemia and Lymphoma. 56. (9). p. 2543-2551.
• (2014). MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis . Blood. 124. (7). p. 1183-1191.
• Mcneil, L.K., Mcneil, L.K., Price, L., Britten, C.M., Jaimes, M., Maecker, H., Odunsi, K., Matsuzaki, J., Staats, J.S., Thorpe, J., et al.(2013). A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI) . Cytometry Part A. 83. (8). p. 728-738.
• Hwa, C., Hwa, C., Price, L.S., Belitskaya-Levy, I., Ma, M.W., Shapiro, R.L., Berman, R.S., Kamino, H., Darvishian, F., Osman, I., et al.(2012). Single versus multiple primary melanomas . Cancer. 118. (17). p. 4184-4192.
• Adusumilli, P.S., Adusumilli, P.S., Gholami, S., Chun, Y.S., Mullerad, M., Chan, M.K., Yu, Z., Ben-Porat, L., Rusch, V.W., Adusumilli, P.S., et al.(2011). Fluorescence-assisted cytological testing (FACT): Ex vivo viral method for enhancing detection of rare cancer cells in body fluids . Molecular Medicine. 17. (7-8). p. 628-634.
• Attig, S., Price, L., Janetzki, S., Kalos, M., Pride, M., McNeil, L., Clay, T., Yuan, J., Odunsi, K., Hoos, A., et al.(2011). A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols . Journal of Translational Medicine. 9. (1).
• Wich, L.G., Ma, M.W., Price, L.S., Sidash, S., Berman, R.S., Pavlick, A.C., Miller, G., Sarpel, U., Goldberg, J.D., Osman, I.(2011). Impact of socioeconomic status and sociodemographic factors on melanoma presentation among ethnic minorities . Journal of Community Health. 36. (3). p. 461-468.
• Moodie, Z., Moodie, Z., Price, L., Gouttefangeas, C., Mander, A., Janetzki, S., Löwer, M., Welters, M.J.P., Ottensmeier, C., Van Der Burg, S.H., et al.(2010). Response definition criteria for ELISPOT assays revisited . Cancer Immunology, Immunotherapy. 59. (10). p. 1489-1501.
• Janetzki, S., Price, L., Britten, C.M., Janetzki, S., Price, L., Britten, C.M., Van Der Burg, S.H., Caterini, J., Currier, J.R., Ferrari, G., et al.(2010). Performance of serum-supplemented and serum-free media in IFNy Elispot Assays for human T cells . Cancer Immunology, Immunotherapy. 59. (4). p. 609-618.
• Sethi, R.A., Stamell, E.F., Price, L., DeLacure, M., Sanfilippo, N.(2010). Head and neck radiotherapy compliance in an underserved patient population . Laryngoscope. 120. (7). p. 1336-1341.
• Fuchsjäger, M.H., Pucar, D., Zelefsky, M.J., Zhang, Z., Mo, Q., Ben-Porat, L.S., Shukla-Dave, A., Wang, L., Reuter, V.E., Hricak, H.(2010). Predicting post-external beam radiation therapy PSA relapse of prostate cancer using pretreatment MRI . International Journal of Radiation Oncology Biology Physics. 78. (3). p. 743-750.
• Britten, C.M., Janetzki, S., Ben-Porat, L., Britten, C.M., Janetzki, S., Ben-Porat, L., Clay, T.M., Kalos, M., Maecker, H., Odunsi, K., et al.(2009). Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium . Cancer Immunology, Immunotherapy. 58. (10). p. 1701-1713.
• Janetzki, S., Panageas, K.S., Ben-Porat, L., Boyer, J., Britten, C.M., Clay, T.M., Kalos, M., Maecker, H.T., Romero, P., Yuan, J., et al.(2008). Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI) . Cancer Immunology, Immunotherapy. 57. (3). p. 303-315.
• Rengan, R., Pfister, D.G., Lee, N.Y., Kraus, D.H., Shah, J.P., Shaha, A.R., Ben-Porat, L.S., Zelefsky, M.J.(2008). Long-term neck control rates after complete response to chemoradiation in patients with advanced head and neck cancer . American Journal of Clinical Oncology: Cancer Clinical Trials. 31. (5). p. 465-469.
• Wright, J.L., Cordeiro, P.G., Ben-Porat, L., Van Zee, K.J., Hudis, C., Beal, K., McCormick, B.(2008). Mastectomy With Immediate Expander-Implant Reconstruction, Adjuvant Chemotherapy, and Radiation for Stage II-III Breast Cancer: Treatment Intervals and Clinical Outcomes . International Journal of Radiation Oncology Biology Physics. 70. (1). p. 43-50.
• Ekenel, M., Iwamoto, F.M., Ben-Porat, L.S., Panageas, K.S., Yahalom, J., DeAngelis, L.M., Abrey, L.E.(2008). Primary central nervous system lymphoma: The role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy . Cancer. 113. (5). p. 1025-1031.
• Berwick, M., Berwick, M., Satagopan, J.M., Ben-Porat, L., Carlson, A., Mah, K., Henry, R., Diotti, R., Milton, K., Pujara, K., et al.(2007). Genetic heterogeneity among fanconi anemia heterozygotes and risk of cancer . Cancer Research. 67. (19). p. 9591-9596.
• Abrey, L.E., Ben-Porat, L., Panageas, K.S., Yahalom, J., Curran, W., Schultz, C., Leibel, S., Nelson, D., Mehta, M., Abrey, L.E., et al.(2007). In reply [9] . Journal of Clinical Oncology. 25. (27). p. 4324-4325.
• Panageas, K.S., Elkin, E.B., Ben-Porat, L., DeAngelis, L.M., Abrey, L.E.(2007). Patterns of treatment in older adults with primary central nervous system lymphoma . Cancer. 110. (6). p. 1338-1344.
• Dalbagni, G., Parekh, D.J., Dalbagni, G., Parekh, D.J., Ben-Porat, L., Potenzoni, M., Herr, H.W., Reuter, V.E.(2007). Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder . BJU International. 99. (2). p. 281-285.
• Panageas, K.S., Panageas, K.S., Ben-Porat, L., Dickler, M.N., Chapman, P.B., Schrag, D.(2007). When you look matters: The effect of assessment schedule on progression-free survival . Journal of the National Cancer Institute. 99. (6). p. 428-432.
• Adusumilli, P.S., Adusumilli, P.S., Stiles, B.M., Chan, M.-K., Mullerad, M., Eisenberg, D.P., Ben-Porat, L., Huq, R., Rusch, V.W., Fong, Y.(2006). Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses . Journal of Gene Medicine. 8. (5). p. 603-615.
• Dalbagni, G., Russo, P., Bochner, B., Ben-Porat, L., Sheinfeld, J., Sogani, P., Donat, M.S., Herr, H.W., Bajorin, D.(2006). Phase II trial of intravesical gemcitabine in bacille Calmette- Guérin-refractory transitional cell carcinoma of the bladder . Journal of Clinical Oncology. 24. (18). p. 2729-2734.
• Ben-Porat, L., Panageas, K.S., Hanlon, C., Patel, A., Halpern, A., Houghton, A.N., Coit, D.(2006). Estimates of stage-specific survival are altered by changes in the 2002 American Joint Committee on Cancer staging system for melanoma . Cancer. 106. (1). p. 163-171.
• Abrey, L.E., Ben-Porat, L., Panageas, K.S., Yahalom, J., Berkey, B., Curran, W., Schultz, C., Leibel, S., Nelson, D., Mehta, M., et al.(2006). Primary central nervous system lymphoma: The memorial sloan-kettering cancer center prognostic model . Journal of Clinical Oncology. 24. (36). p. 5711-5715.
• D'Angelica, M., Maddineni, S., D'Angelica, M., Maddineni, S., Fong, Y., Martin, R.C.G., Cohen, M.S., Ben-Porat, L., Gonen, M., DeMatteo, R.P., et al.(2006). Optimal abdominal incision for partial hepatectomy: Increased late complications with Mercedes-type incisions compared to extended right subcostal incisions . World Journal of Surgery. 30. (3). p. 410-418.
• Zelefsky, M.J., Ben-Porat, L., Chan, H.M., Fearn, P.A., Venkatraman, E.S.(2006). Evaluation of postradiotherapy PSA patterns and correlation with 10-year disease free survival outcomes for prostate cancer . International Journal of Radiation Oncology Biology Physics. 66. (2). p. 382-388.
• Shah, N.T., Kris, M.G., Pao, W., Shah, N.T., Kris, M.G., Pao, W., Tyson, L.B., Pizzo, B.M., Heinemann, M.-H., Ben-Porat, L., et al.(2005). Practical management of patients with non-small-cell lung cancer treated with gefitinib . Journal of Clinical Oncology. 23. (1). p. 165-174.
• Adusumilli, P.S., Eisenberg, D.P., Chun, Y.S., Ryu, K.-W., Ben-Porat, L., Hendershott, K.J., Chan, M.-K., Huq, R., Riedl, C.C., Fong, Y.(2005). Virally directed fluorescent imaging improves diagnostic sensitivity in the detection of minimal residual disease after potentially curative cytoreductive surgery . Journal of Gastrointestinal Surgery. 9. (8). p. 1138-1147.
• Hale, E.K., Stein, J., Ben-Porat, L., Panageas, K.S., Eichenbaum, M.S., Marghoob, A.A., Osman, I., Kopf, A.W., Polsky, D.(2005). Association of melanoma and neurocutaneous melanocytosis with large congenital melanocytic naevi - Results from the NYU-LCMN registry . British Journal of Dermatology. 152. (3). p. 512-517.
• Kalish, R.S., Kalish, R.S., Dellavalle, R.D., Johnson, K.R., Autier, P., Severi, G., Boniol, M., De Vries, E., Coebergh, J.-W., Doré, J.-F., et al.(2005). Re: Sun exposure and mortality from melanoma (multiple letters) [1] . Journal of the National Cancer Institute. 97. (15). p. 1158-1162.
• Berwick, M., Armstrong, B.K., Ben-Porat, L., Fine, J., Kricker, A., Eberle, C., Barnhill, R.(2005). Sun exposure and mortality from melanoma . Journal of the National Cancer Institute. 97. (3). p. 195-199.
• Omuro, A.M.P., Ben-Porat, L.S., Panageas, K.S., Kim, A.K., Correa, D.D., Yahalom, J., DeAngelis, L.M., Abrey, L.E.(2005). Delayed neurotoxicity in primary central nervous system lymphoma . Archives of Neurology. 62. (10). p. 1595-1600.
• Panageas, K.S., Elkin, E.B., DeAngelis, L.M., Ben-Porat, L., Abrey, L.E.(2005). Trends in survival from primary central nervous system lymphoma, 1975-1999: A population-based analysis . Cancer. 104. (11). p. 2466-2472.
• Pothuri, B., Montemarano, M., Gerardi, M., Shike, M., Ben-Porat, L., Sabbatini, P., Barakat, R.R.(2005). Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma . Gynecologic Oncology. 96. (2). p. 330-334.
• Allen, P.J., Nissan, A., Picon, A.I., Kemeny, N., Dudrick, P., Ben-Porat, L., Espat, J., Stojadinovic, A., Cohen, A.M., Fong, Y., et al.(2005). Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: An institutional experience of 544 consecutive cases . Journal of the American College of Surgeons. 201. (1). p. 57-65.
• Zaider, M., Zelefsky, M.J., Cohen, G.N., Chui, C.-S., Yorke, E.D., Ben-Porat, L., Happersett, L.(2005). Methodology for biologically-based treatment planning for combined low-dose-rate (permanent implant) and high-dose-rate (fractionated) treatment of prostate cancer . International Journal of Radiation Oncology Biology Physics. 61. (3). p. 702-713.
• Adusumilli, P.S., Chan, M.-K., Ben-Porat, L., Mullerad, M., Stiles, B.M., Tuorto, S., Fong, Y.(2005). Citation characteristics of basic science research publications in general surgical journals . Journal of Surgical Research. 128. (2). p. 168-173.
• Zelefsky, M.J., Ben-Porat, L., Scher, H.I., Chan, H.M., Fearn, P.A., Fuks, Z.Y., Leibel, S.A., Venkatraman, E.S.(2005). Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer . Journal of Clinical Oncology. 23. (4). p. 826-831.
• Bentrem, D.J., Bentrem, D.J., Okabe, S., Wong, W.D., Guillem, J.G., Weiser, M.R., Temple, L.K., Ben-Porat, L.S., Minsky, B.D., Cohen, A.M., et al.(2005). T1 adenocarcinoma of the rectum: Transanal excision or radical surgery? . Annals of Surgery. 242. (4). p. 472-479.
• Bowne, W.B., Lee, B., Wong, W.D., Ben-Porat, L., Shia, J., Cohen, A.M., Enker, W.E., Guillem, J.G., Paty, P.B., Bowne, W.B., et al.(2005). Operative salvage for locoregional recurrent colon cancer after curative resection: An analysis of 100 cases . Diseases of the Colon and Rectum. 48. (5). p. 897-909.
• Hawkins, W.G., Busam, K.J., Hawkins, W.G., Busam, K.J., Hawkins, W.G., Busam, K.J., Ben-Porat, L., Panageas, K.S., Coit, D.G., Gyorki, D.E., et al.(2005). Desmoplastic melanoma: A pathologically and clinically distinct form of cutaneous melanoma . Annals of Surgical Oncology. 12. (3). p. 207-213.
• Jarnagin, W.R., Jarnagin, W.R., Bowne, W., Klimstra, D.S., Ben-Porat, L., Roggin, K., Cymes, K., Fong, Y., DeMatteo, R.P., D'Angelica, M., et al.(2005). Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma . Annals of Surgery. 241. (5). p. 703-714.
• Hawkins, W.G., DeMatteo, R.P., Jarnagin, W.R., Ben-Porat, L., Blumgart, L.H., Fong, Y.(2004). Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer . Annals of Surgical Oncology. 11. (3). p. 310-315.
• Satagopan, J.M., Ben-Porat, L., Berwick, M., Robson, M., Satagopan, J.M., Ben-Porat, L., Berwick, M., Robson, M., Kutler, D., Auerbach, A.D.(2004). A note on competing risks in survival data analysis . British Journal of Cancer. 91. (7). p. 1229-1235.
• Stanziale, S.F., Petrowsky, H., Adusumilli, P.S., Ben-Porat, L., Gonen, M., Fong, Y.(2004). Infection with Oncolytic Herpes Simplex Virus-1 Induces Apoptosis in Neighboring Human Cancer Cells: A Potential Target to Increase Anticancer Activity . Clinical Cancer Research. 10. (9). p. 3225-3232.
• Janetzki, S., Schaed, S., Blachere, N.E.B., Ben-Porat, L., Houghton, A.N., Panageas, K.S.(2004). Evaluation of Elispot assays: Influence of method and operator on variability of results . Journal of Immunological Methods. 291. (1-2). p. 175-183.
• Miller, V.A., Kris, M.G., Shah, N., Patel, J., Azzoli, C., Gomez, J., Krug, L.M., Pao, W., Rizvi, N., Pizzo, B., et al.(2004). Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer . Journal of Clinical Oncology. 22. (6). p. 1103-1109.
• Prasad, M., Ben-Porat, L., Hoppe, B., Aghajanian, C., Sabbatini, P., Chi, D.S., Hensley, M.L., Prasad, M., Ben-Porat, L., Hoppe, B., et al.(2004). Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer . Gynecologic Oncology. 93. (1). p. 223-228.
• Wagner, J.E., Tolar, J., Levran, O., Scholl, T., Deffenbaugh, A., Satagopan, J., Ben-Porat, L., Mah, K., Batish, S.D., Wagner, J.E., et al.(2004). Germline mutations in BRCA2: Shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia . Blood. 103. (8). p. 3226-3229.
• Adusumilli, P.S., Ben-Porat, L., Pereira, M., Roesler, D., Leitman, I.M.(2004). The prevalence and predictors of herbal medicine use in surgical patients . Journal of the American College of Surgeons. 198. (4). p. 583-590.
• Ulaner, G.A., Huang, H.-Y., Otero, J., Zhao, Z., Ben-Porat, L., Satagopan, J.M., Gorlick, R., Meyers, P., Healey, J.H., Huvos, A.G., et al.(2003). Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma . Cancer Research. 63. (8). p. 1759-1763.
• Kooby, D.A., Stockman, J., Ben-Porat, L., Gonen, M., Jarnagin, W.R., Dematteo, R.P., Tuorto, S., Wuest, D., Blumgart, L.H., Fong, Y., et al.(2003). Influence of Transfusions on Perioperative and Long-Term Outcome in Patients Following Hepatic Resection for Colorectal Metastases . Annals of Surgery. 237. (6). p. 860-870.
• Zelefsky, M.J., Yamada, Y., Marion, C., Sim, S., Cohen, G., Ben-Porat, L., Silvern, D., Zaider, M.(2003). Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy . International Journal of Radiation Oncology Biology Physics. 55. (4). p. 956-963.
• Kutler, D.I., Wreesmann, V.B., Goberdhan, A., Ben-Porat, L., Kutler, D.I., Wreesmann, V.B., Goberdhan, A., Ben-Porat, L., Satagopan, J., Ngai, I., et al.(2003). Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients . Journal of the National Cancer Institute. 95. (22). p. 1718-1721.
• Moher, D., Soeken, K., Sampson, M., Ben-Porat, L., Berman, B.(2002). Assessing the quality of reports of systematic reviews in pediatric complementary and alternative medicine . BMC Pediatrics. 2.
• Stanziale, S.F., Petrowsky, H., Joe, J.K., Roberts, G.D., Zager, J.S., Gusani, N.J., Ben-Porat, L., Gonen, M., Fong, Y.(2002). Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase . Surgery. 132. (2). p. 353-359.
• Allen, P.J., Stojadinovic, A., Ben-Porat, L., Allen, P.J., Stojadinovic, A., Ben-Porat, L., Gonen, M., Kooby, D., Blumgart, L., Paty, P., et al.(2002). The management of variant arterial anatomy during hepatic arterial infusion pump placement . Annals of Surgical Oncology. 9. (9). p. 875-880.
• Jarnagin, W.R., Jarnagin, W.R., Gonen, M., Fong, Y., DeMatteo, R.P., Ben-Porat, L., Little, S., Corvera, C., Weber, S., Blumgart, L.H., et al.(2002). Improvement in perioperative outcome after hepatic resection: Analysis of 1,803 consecutive cases over the past decade . Annals of Surgery. 236. (4). p. 397-407.

BOOK
• Moodie, Z., Price, L., Janetzki, S., Britten, C.M.(2012). Response determination criteria for ELISPOT: Toward a standard that can be applied across laboratories . Methods in Molecular Biology. 792. p. 185-196.